We have recently shown that Daratumumab therapy rapidly depletes CD38+ Tregs, MDSCs and Bregs in the peripheral blood and in the BMand is associated with clonal expansion of CD4+ and CD8+ T-cells in MM patients [25]. This evidence concerns the gene CD38 and Miyoshi myopathy.